Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an <i>in silico</i> modelling study.

"JO’N has no conflicts of interest that are directly relevant to the content in this article. DMT has received research funding from Janssen Pharmaceuticals and Lundbeck but no sources of funding were received for the preparation of this article. He has also received speaking honoraria from Janssen, Otsuka, Viatris, Lundbeck, Sunovion and Recordati. MAH is the clinical research fellow on the NIHR-funded RADAR study examining reduction and discontinuation of antipsychotic medication in people with psychotic disorders, including depot medication. He is an unpaid associate of the International Institute of Psychiatric Drug Withdrawal and a member of the Tapering Antipsychotics and Evaluating Recovery (TAPER) group consisting of international psychiatric researchers."

"Funding: The authors received no financial support for the research, authorship and/or publication of this article."